Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Wulff

Medical Oncology Westwood, KS Medical Doctor

NPI 1326362989 CMS profile 3956899

2650 Shawnee Mission Pkwy, Westwood, KS 66205

Open in the dashboard

General payments

$65,193

99 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$464,097 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Elizabeth Wulff of Westwood, KS is reported in the CMS Open Payments database as having received $65,193 across 99 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $464,097 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,445 48
2024 General $7,654 19
2023 General $6,698 7
2022 General $6,007 19
2021 General $3,710 4
2020 General $1,679 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Wulff
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Elizabeth Wulff were reported at $39,445. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Elizabeth Wulff Medical Oncology median Middle half National median
2019 $0 $968 $140–$6,658 $163
2020 $1,679 $747 $102–$5,891 $114
2021 $3,710 $430 $50–$4,098 $132
2022 $6,007 $812 $127–$4,907 $149
2023 $6,698 $957 $144–$5,248 $160
2024 $7,654 $1,042 $149–$5,650 $164
2025 $39,445 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Exelixis Inc. $29,308 50 payments
  2. EMD Serono, Inc. $11,765 4 payments
  3. E.R. Squibb & Sons, L.L.C. $7,849 8 payments
  4. Janssen Biotech, Inc. $5,298 13 payments
  5. AstraZeneca Pharmaceuticals LP $4,862 4 payments
  6. Aveo Pharmaceuticals, Inc. $2,651 12 payments
  7. Pfizer Inc. $1,778 3 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $1,102 1 payment
  9. Astellas Pharma Global Development $395 1 payment
  10. Daiichi Sankyo Inc. $124 1 payment
  11. Other $61 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $44,483 16 payments
  2. Travel and Lodging $6,632 34 payments
  3. Honoraria $5,690 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,950 2 payments
  5. Food and Beverage $2,948 39 payments
  6. Entertainment $392 3 payments
  7. Education $97 3 payments
Products named General payments · program years 2020–2025
  1. CABOMETYX Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) $20,796 35 payments
  2. CABOMETYX Oncology $8,512 15 payments
  3. ERLEADA $5,298 13 payments
  4. AKEEGA $5,192 10 payments
  5. FOTIVDA $2,516 11 payments
  6. OPDIVO $1,890 1 payment
  7. TALZENNA $1,500 1 payment
  8. Nubeqa $1,102 1 payment
  9. PADCEV Oncology $395 1 payment
  10. Padcev Oncology $143 1 payment
  11. Other $104 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,290

Median for Medical Oncology: 414

Drug cost

$2,151,111

Median for Medical Oncology: $849,427

Branded share of claims

25%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 34 $458,991
Cabometyx Cabozantinib S-Malate Brand 21 $455,696
Welireg Belzutifan Brand 18 $345,946
Inlyta Axitinib Brand 16 $329,741
Fotivda Tivozanib Hcl Brand 12 $327,106
Abiraterone Acetate Generic 102 $122,214
Orgovyx Relugolix Brand 16 $44,040
Eliquis Apixaban Brand 14 $16,552
Xarelto Rivaroxaban Brand 19 $15,133
Xtampza Er Oxycodone Myristate Brand 14 $5,803

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$64,801

Medicare's payments for the services billed

Medicare patients

247

Average age 74

Services billed

1,236

63 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 56%
Ischemic heart disease 49%
Chronic kidney disease 35%
Diabetes 31%
Depression 28%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CABOMETYX
  • Exelixis Inc. $4,983
$4,983 21 —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $221
$221 12 —
Padcev
  • PFIZER INC. $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record